Novo Nordisk to pay ZymoGenetics up to $182 million for IL-21 MAb
This article was originally published in Scrip
Executive Summary
Novo Nordisk has paid ZymoGenetics $24 million up front and pledged up to a further $157.5 million in milestone payments for a pre-IND fully human monoclonal antibody and related IP rights.